WuXi XDC Cayman Inc. (HKG: 2268)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
27.90
-0.10 (-0.36%)
Jan 28, 2025, 12:08 PM HKT
10.71%
Market Cap 33.43B
Revenue (ttm) 3.00B
Net Income (ttm) 638.84M
Shares Out 1.20B
EPS (ttm) 0.53
PE Ratio 52.78
Forward PE 30.06
Dividend n/a
Ex-Dividend Date n/a
Volume 557,900
Average Volume 6,512,462
Open 27.55
Previous Close 28.00
Day's Range 27.30 - 28.10
52-Week Range 12.08 - 33.60
Beta n/a
RSI 42.21
Earnings Date Mar 26, 2025

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China.... [Read more]

Sector Healthcare
Founded 2013
Employees 1,178
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2268
Full Company Profile

Financial Performance

In 2023, WuXi XDC Cayman's revenue was 2.12 billion, an increase of 114.44% compared to the previous year's 990.42 million. Earnings were 283.54 million, an increase of 82.07%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.